The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

Inclusion Criteria: 1. Age ≥ to 18 years old 2. Admission to intensive care unit for traumatic brain injury or subarachnoid hemorrhage without other life-threatening injury 3. Patients under sedation with administration of opiate-agonists, μ receptor agonists (Sufentanil, Fentanyl, Remifentanil, Morphine) for less than 24 hours 4. Expected duration of invasive mechanical ventilation and sedation of 48 hours or more 5. Intracranial pressure monitoring 6. Enteral feeding by oro / nasogastric tube 7. Affiliated or beneficiary of the French social security system Exclusion Criteria: 1. Patient who received opioids for more than 24 hours 2. Patient with refractory intracranial hypertension at the time of inclusion: intracranial hypertension requiring therapy other than analgo-sedation (thiopental, targeted temperature management, decompressive craniectomy) 3. Acute or chronic renal failure with creatinine clearance \<60ml / min 4. Known or suspected acute gastrointestinal obstruction 5. Risk of digestive perforation: * history of peptic ulcer * Crohn's disease * Ogilvie syndrome * acute diverticulitis * infiltrating gastrointestinal tumor * recurrent or advanced ovarian cancer * peritoneal metastasis * recent abdominal trauma with risk of digestive perforation 6. Concomitant treatment with a strong or moderate inhibitory effect of CYP 3A4 (For example: clarithromycin, ketaconazole, itraconazole, telithromycin, ritonavir, indinavir, saquinavir) or with a strong inducing effect (carbamazepin, rifampicin, millepertuis) 7. Concomitant treatment with vascular endothelial growth factor (VEGF) inhibitor 8. Allergy to Naloxegol or one of its excipients 9. Recent history of myocardial infarction within the past 6 months, symptomatic congestive cardiovascular disease, QT ≥ 500 msec 10. Patient with a medical decision for rapid palliative care 11. Pregnancy and / or breastfeeding 12. Child Pugh C stage cirrhosis 13. Patient under legal protection or deprived of liberty 14. Patient with another life-threatening injury 15. History of clinically important alterations of the blood-brain barrier: primary brain tumors, metastasis or other inflammatory pathologies in the CNS, active multiple sclerosis, Alzheimer's disease at an advanced stage.